The expression of GLUT-1 and VEGF-A mRNA in the rectal cancer patients with neoadjuvant chemoradiation

Sri Nuryani Wahyuningrum; Christina Prihharsanti; Sofia Mubarika Haryana; Ahmad Ghozali; Firly Putri Fardhila

doi:10.22435/hsji.v11i2.3149

Sri Nuryani Wahyuningrum Center for Health Research and Development of Magelang, National Institute of Health Research and Developmen (Badan Litbang Kesehatan)t
Christina Prihharsanti Department of Radiology, dr. Kariadi Hospital, Semarang
Sofia Mubarika Haryana Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta
Ahmad Ghozali
Firly Putri Fardhila

DOI: https://doi.org/10.22435/hsji.v11i2.3149

Keywords: rectal cancer, chemoradiotherapy, GLUT-1, VEGF-A, prognosis

Abstract

Latar belakang: Angka kekambuhan dan resistensi pasien kanker rektum mencapai 40 persen. Kondisi tersebut bisa disebabkan karena peningkatan ekspresi GLUT-1 dan VEGF-A, serta mempengaruhi prognosis pasien. Tujuan penelitian ini adalah untuk mengetahui korelasi ekspresi mRNA GLUT-1 dan VEGF-A, serta hubungannya dengan prognosis pasien kanker rektum yang menjalani kemoradiasi.

Metode: Penelitian Kohor ini melibatkan 16 orang pasien kanker rektum lokal stadium II atau III yang menjalani kemoradiasi di RSUP Kariadi Semarang. Sampel darah intravena diambil 5 mL pada saat sebelum dan sesudah kemoradiasi. Total RNA diisolasi dari 200 μl serum, kemudian dilakukan sintesis cDNA. Ekspresi mRNA GLUT-1 dan VEGF-A dikuantifikasi dengan metode Livak menggunakan reference gene β-actin.

Hasil: Rata-rata ekspresi mRNA GLUT-1 menurun signifikan 2,14 kali (P=0,044) dan mRNA VEGF-A menurun 1,9 kali (P = 0,03). Ekspresi mRNA GLUT-1 dan VEGF-A berkorelasi positif kuat dan signifikan pada saat sebelum (r = 0,6; R2 = 0,455; P = 0,013) dan sesudah kemoradiasi (r = 0,8; R2 = 0,598; P < 0,001). Peningkatan ekspresi mRNA GLUT-1 berhubungan dengan prognosis buruk pasien, dengan resiko 18 kali lebih tinggi (P=0,036; OR=18, 95% CI=1,2 – 261). Peningkatan ekspresi mRNA VEGF-A tidak berhubungan signifikan dengan prognosis pasien (P=0,12; OR=9; 95%CI=0,6-123).

Kesimpulan: Ekspresi mRNA GLUT-1 dan VEGF-A berkorelasi positif dan saling mempengaruhi satu dengan lainnya. Peningkatan ekspresi mRNA GLUT-1 berhubungan dengan prognosis buruk pasien. Hasil penelitian ini mengindikasikan bahwa ekspresi mRNA GLUT-1 dari sampel darah berpotensi sebagai biomarker prognosis pada pasien kanker rektum yang menjalani kemoradiasi.

Kata kunci: kanker rektum, kemoradiasi, GLUT-1, VEGF-A, prognosis

Abstract

Background: Rectal cancer patients have 40 percent risk of recurrence and resistance, which is triggered by increasing in GLUT-1 and VEGF-A mRNA expression. This condition associate with the patients prognosis. This study aimed to determine the correlation between GLUT-1 and VEGF-A mRNA expression, and analyze its association with the rectal cancer patients prognosis who received chemoradiation.

Methods: This was a Cohort study involving 16 rectal cancer patients with stage II or III undergoing chemoradiation at Kariadi Hospital Semarang. Five milliliters of intravenous blood samples were taken before and after chemoradiation. Total RNA was isolated from 200 μl of blood serum, followed by cDNA synthesis. GLUT-1 and VEGF-A mRNA expression was quantified by the Livak method using β-actin as a reference gene.

Results: GLUT-1 and VEGF-A mRNA expression decreased significantly 2.14 times (P=0,044) and 1,9 times (P=0,03), respectively. Expression of GLUT-1 and VEGF-A mRNA have a significant and strong positive correlation at before (r=0,6; R2=0,455; P=0,013) and after chemoradiation (r=0,8; R2=0,598; P<0,001). GLUT-1 mRNA expression enhancement significantly associate with poor prognosis and risk 18 times of worse prognosis (P=0,036; OR=18, 95% CI=1,2–261). VEGF-A mRNA expression did not associate with patient prognosis (P=0,12; OR=9; 95%CI=0,6-123).

Conclusion: Expression of GLUT-1 and VEGF-A mRNA have a significant and strong positive correlation. GLUT-1 mRNA expression enhancement significantly associate with the poor prognosis of the rectal cancer patients. Our finding suggests that GLUT-1 mRNA expression from blood sample was potential as a biomarker to predict rectal cancer patient prognosis who received chemoradiation

Keywords: rectal cancer, chemoradiotherapy, GLUT-1, VEGF-A, prognosis

References

WHO.int [Internet]. Geneva: World Health Organization (WHO), Cancer; c2017-19 [updated 2018 Sep 12; cited 2019 Des 10]. Available from: URL:https://www.who.int/newsroom/ factsheets/detail/ cancer.

Gaertner WB, Kwaan MR, Madoff RD, Melton GB. Rectal cancer: an evidence-based update for primary care providers. World J Gastroenterol. 2015;21(25): 7659-71 Doi: 10.3748/wjg.v21.i25.7659.

Lim SH, Chua W, Henderson C, Ng W, Shin JS, Chantrill L, et al. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Cri Rev Oncol. Hematol. 2015;96(1):67–80. Doi: https://doi.org/ 10.1016/j.critrevonc.2015.05.003.

Chen M, Chen L, Xu L, Zhag J, Song X. Neoadjuvant chemoradiation for locally advanced rectal cancer: a systematic review of the literature with network meta-analysis. Cancer Manag. Res. 2019;11:741–58. Doi :10.2147/CMAR.S189445.

Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis and resistance to therapy. Hypoxia (Auckl). 2015;3:83-92. Doi :https: //doi.org/10.2147/HP.S93413.

Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int. J Nanomed. 2018;13:6049-58.

Horsman MR, Overgaard J. The impact of hypoxia and its modification of the outcome of radiotherapy. J. Radiat. Res. 2016;57 (S1):i90-i98.

Yu XJ, Song JC, Du J, Shi YQ, Liu YX, Shen Y. GLUT-1 and its regulating factor HIF-1a expression in epithelial ovarian tumors: GLUT-1 is associated with molecular typing and grade of epithelial ovarian cancer. Int. J. Exp. Pathol. 2017;10(4):4479-87.

Epstein T, Gatenby RA, Brown JS. The Warburg effect as an adaptation on cancer cells to rapid fluctuations in energy demand. Plos ONE. 2017;12(9)e0185085:1-14. Doi: https://doi.org/ 10.1371/journal.pone.0185085.

Chung FY, Huang MY, Yeh CS, Chang HJ, Cheng TL, Yen LC, et al. Glut-1 gene is a potential hypoxic marker in colorectal cancer patient. BMC Cancer. 2009;9(241):1-11. Doi : 10.1186/1471-2407-9-241.

Arcondeguy T, Lacazette E, Millevoi S, Prats H, Touriol C. VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic Acids Res. 2013;41(17):7997–8010 Doi:10.1093/nar/gkt539.

Bendardaf R, El-Serafi A, Syrjanen K, Collan Y, Pyrhonen S. The effect of vascular endothelial growth factor-1 expression on survival of advanced colorectal cancer patients. Lybian J. Med. 2017;12:1-5. Doi : http://dx.doi.org/ 10.1080/19932820.2017.1290741.

Conde-Muino R, Cuadros M, Zambudio N, Segura-Jimenez I, Cano C, Palma P. Predictive biomarkers to chemoradiation in locally advanced rectal cancer. BioMed Res. Int. 2015;921435:1-10. Doi:http://dx.Doi.org/10.1155/ 2015/921435.

Al Tameemi W, Dale TP, Al-Jumaily RMK, Forsyth NR. Hypoxia-modified cancer cell metabolism. Frontiers in cell and development biology. Front. Cell Dev. Biol. 2019;7(4):1-15. Doi: 10.3389/fcell.2019.00004.

Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: implications for cancer detection, prognosis and treatment. Metabolism. 2016;65:124–39. doi: 10.1016/j.metabol.2015.10.007.

Shibuya K, Okada M, Suzuki S, Seino M, Seino S, Takeda H, et al. Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget. 2015;6:651–61. Doi: 10.18632/oncotarget.2892.

Trendowski M, Mitchell JM, Corsette CM, Acquafondata C, Fondy TP. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest. New Drugs 2015;33:290–9. doi: 10.1007/s10637 014- 0203-5.

Brophy S, Sheehan KM, McNamara DA, Deasy J, Bouchier-Hayes DJ, Kay EW. GLUT-1 expression and response to chemoradiotherapy in rectal cancer. Int. J. Cancer. 2009;125:2778-82.

Buka D, Dvorak J, Sitorova V, Sirak I, Voboril R, Melichar B, et al. The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma. Contemp. Oncol. 2017;21(1):48-53. Doi: http://Doi.org/10.5114/wo. 2017.66656.

Bendardaf R, El-Serafi A, Syrjanen K, Collan Y, Pyrhonen S. The effect vascular endothelial growth factor-1 expression on survival of advanced colorectal cancer patients. Lybian J. Med. 2017;12:1-5. Doi: http://dx.doi.org/ 10.1080/19932820.2017.1290741.

Wahyuningrum SN. Expression of miR-124-3p, carbohydrate kinase-like (CARKL) mRNA, and VEGF-A mRNA as markers of tumor-associated macrophage (TAM) metabolic reprogramming in rectal cancer patients at before and after chemoradiation [Thesis]. Yogyakarta: Universitas Gadjah Mada; 2019.

Lv X, Li J, Zhang C, Hu T, Li S, He S, et al. The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism. Genes Dis. 2017;4:19-24. Doi :http://dx.doi.org/10.1016/j.gendis.2016.11. 003.

Sone H, Deo BK, Kumagai AK. Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells. Investig. Ophthalmol. Vis. 2000;Sci 41:1876–1884.

Yeh WL, Lin CJ, Fu WM. Enhancement of glucose transporter expression of brain endhotelial cells by vascular endhotelial growth factor derived from glioma exposed to hypoxia. Mol. Pharmacol. 2008;73:170-7.

Fang J, Zhou SH, Fan J, Yan SX. Roles of glucose transporter-1 and the phosphatidylinositol 3-kinase/protein kinase B pathway in cancer radioresistance. Mol. Med. Rep. 2015;11:1573-81.

The expression of GLUT-1 and VEGF-A mRNA in the rectal cancer patients with neoadjuvant chemoradiation

Abstract

References

Most read articles by the same author(s)